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Background: ST-elevation myocardial infarction (STEMI) is associated with increased 
inﬂ ammation and oxidative stress, enhancing the formation of Advanced Glycation 
Endproducts (AGEs). Some AGEs encompass a characteristic ﬂ uorescence pattern, which 
can be non-invasively measured as skin autoﬂ ourescence (AF). In this study we investigate 
whether skin AF is elevated in STEMI, its association with inﬂ ammatory and glycemic stress 
and its predictive value for clinical outcomes.
Methods: Skin AF was measured in 88 STEMI patients (age: 64±13 years; male: 76%; 
diabetes: 28%) within 72 hours following symptom onset and >150 days after discharge, in 
81 stable coronary artery disease (sCAD) patients (age: 64±10 years; male: 74%; diabetes: 
15%), and in 32 healthy controls (age: 63±11 years; male: 72%). The cumulative one year 
incidence of all cause mortality and hospitalization for myocardial infarction or heart failure 
was documented. 
Results: Skin AF was signiﬁ cantly higher in STEMI compared with sCAD and controls, 
irrespective of confounders, and was independently associated with HbA1c and C-reactive 
protein. Skin AF decreased signiﬁ cantly in STEMI patients, when measured >200 days after 
discharge. In STEMI patients, skin AF above the median was predictive of future events 
(hazard ratio, 11.6; 95% CI, 1.5-90.8; P=0.019), even after partial correction for known 
confounders.
Conclusion: Skin AF is elevated in STEMI, is associated with inﬂ ammation and glycemic 











































Oxidative stress plays a pivotal role in the inﬂ ammatory process leading to atherosclerotic 
plaque formation1. In clinical studies, several novel markers of oxidative stress have been 
found to be associated with acute coronary syndromes (ACS) and also to predict future 
cardiovascular events, independent of traditional cardiovascular risk factors2-6. However, 
since the measurement of most of the biomarkers requires sophisticated techniques, clinical 
applicability is limited. 
Oxidative modiﬁ cation of carbohydrates and lipids enhances the formation of Advanced 
Glycation Endproducts and Advanced Lipoxidation Endproducts, generally referred to as 
AGEs. Although classically associated with diabetes and renal failure7, these compounds 
are also implicated in the pathophysiology of atherosclerosis8. We developed a device to 
non-invasively assess skin accumulation of AGEs by measuring skin autoﬂ uorescence (AF). 
It has been validated with glycaemic and oxidative stress derived AGEs measured in skin 
biopsies and independently predicts cardiovascular mortality in patients with renal failure 
and in patients with type 2 diabetes9;10.  Furthermore, we have recently demonstrated that 
skin AF is elevated in patients with stable coronary artery disease (sCAD) and is associated 
with neopterin, a serum monocyte activation marker and with serum levels of the soluble 
isoform of the receptor for AGEs (sRAGE), making it a potentially non-invasive marker for 
the inﬂ ammatory process that characterizes atherosclerosis11. 
In this study we investigate whether skin AF is elevated in acute ST-elevation myocardial 
infarction (STEMI) compared with sCAD and healthy controls. Furthermore, we investigate 
whether skin AF is associated with clinically available markers of inﬂ ammation and glycaemic 
stress in these patients, and whether it predicts the one year incidence of major adverse 
cardiac events (MACE) in STEMI.
Materials and Methods
Subjects
This observational study was performed between May 2004 and August 2005, including 
88 patients with acute STEMI admitted to our Coronary Care Unit and 81 patients with 
sCAD admitted for elective coronary angiography (CAG). Diagnostic criteria for STEMI were: 
typical chest pain of >30 minutes duration and signiﬁ cant ST segment elevation of >1 mm 
(0.1 mV) in more than 2 adjacent leads on electrocardiography. sCAD was deﬁ ned as typical 
chest pain, or a history of an ACS, or vascular intervention, combined with the presence of at 
least one coronary artery with mild stenosis (>30% luminal narrowing) on CAG. Additionally, 
31 healthy age and sex matched controls without a history of cardiovascular disease (CVD), 
with <2 vascular risk factors, and with normal carotid and femoral arteries on ultrasound 
examination, were recruited by advertisement in a local newspaper. Exclusion criteria were: 
recent ACS <3 months before admission, known renal disease or serum creatinine >1.7 
mg/dL at admission, severe inﬂ ammatory or current malignant disease, and skin photo type 
V/VI (i.e. a skin of colour). The study was approved by the local ethics committee and all 









Follow-up measurement and event scoring
After discharge, STEMI patients were routinely prescribed statins, β-blocking agents, aspirin, 
and clopidogrel. In a subgroup of 29 STEMI patients a second skin AF measurement was 
performed >150 days after STEMI. Since most patients were transferred back to a regional 
hospital <3 days after percutaneous coronary intervention (PCI), it was not possible to 
perform this measurement in all initial STEMI patients. Additionally, for all STEMI patients 
the one year incidence of all cause mortality and hospitalization for myocardial infarction or 
heart failure was documented (major adverse cardiac events (MACE)). Event scoring was 
performed blinded for patient characteristics and skin AF levels, obtained from questionnaires 
and veriﬁ ed with patient’s hospital records. Non responders were contacted by telephone 
or their status was veriﬁ ed with the family doctor. Three patients were lost to follow-up. 
Myocardial infarction was deﬁ ned as typical clinical presentation, combined with troponine 
levels above normal or typical ECG changes, and heart failure was deﬁ ned as hospitalization 
for New York Heart Association (NYHA) Class III or IV heart failure. 
Skin Autoﬂ uorescence
Skin AF was assessed on the ventral site of the lower arm with a prototype of the current 
AGE-Reader (DiagnOptics BV, Groningen, The Netherlands) as described elsewhere12;13. 
In short, the AGE-Reader consists of a tabletop box, containing a black light excitation 
light source (peak wavelength ~360 nm). Light emitted from the skin is measured with 
an integrated spectrometer. Measurement is fully automated and takes approximately 30 
seconds to complete, giving an average value over 50 individual scans. Skin AF is calculated 
by dividing the mean value of the emitted light intensity per nm between 420-600 nm by 
the mean value of the excitation light intensity per nm between 300-420 nm, expressed as 
arbitrary units (AU). The intra-individual Altman error percentage is 5.0% on a single day 
and 5.9% for seasonal changes12.
Laboratory assessments
Laboratory parameters were routinely measured at the local clinical laboratory and collected 
at admission, prior to CAG/PCI in sCAD and prior to or shortly after PCI in STEMI. However, 
since no admission blood was collected from approximately 20% of sCAD patients, the 
most recent (<3 months before study entry) values were used. C-reactive protein (CRP) 
was measured on a normal sensitivity machine with detection limit of 4 mg/dl (Vitros 250; 
Ortho Clinical Diagnostics, Rochester, USA). Creatinine clearance was estimated with the 
Cockcroft-Gault formula.
Statistical analysis
Based on a pilot study of 37 STEMI patients, we determined that a sample size of 85 
STEMI and sCAD patients would have 80% power to detect a difference of at least 10% at 
α=0.05 between STEMI and sCAD patients14. Normal distribution of variables was tested 
with the Kolmogorov-Smirnov test. For comparison between groups, continuous variables 
were analyzed by analysis of variance with correction for multiple comparisons (Bonferroni). 
In case of categorical variables the Fisher’s exact test was used. Descriptive statistics are 










































as percentages. To test whether between-group differences in skin AF could be explained 
by differences in potential confounders, one-way analysis of covariance (ANCOVA) was 
performed and F statistic and estimation of effect size (eta-squared, η2) were calculated. 
Skewed variables (i.e. glucose, HbA1c, triglycerides, and peak cardiac enzymes) were 
log transformed for a better linear ﬁ t. CRP was analysed as a dichotomous variable with 
separation by values above and below 4 mg/d. The Pearson correlation or Mann-Whitney 
test were used as appropriate for unadjusted associations. Stepwise, forward selection 
was used to construct multivariate models and variables with P-values <0.05 which were 
retained in the model. The one-year survival period after STEMI until the occurrence of the 
composite endpoint was assessed by the Kaplan–Meier method and comparison was made 
between STEMI patients with skin AF values above and below the median, using the log-rank 
test. For assessment of the inﬂ uence of confounding factors on skin AF as a predictor of the 
composite endpoint, Cox proportional hazard method was used. Due to the small sample 
size and thus a low number of events, we could only correct for one potential confounder 
at a time. The following covariates were corrected for separately:  age, sex, smoking, peak 
troponin levels, anterior infarct location, previous myocardial infarction, and admission 
blood pressure, glucose, and serum creatinine. Since CRP and HbA1c were measured in 
only 64 and 74 STEMI patients respectively, these values were not included in this analysis.
A two-sided P-value <0.05 was considered statistically signiﬁ cant. All statistical analyses 




Subject characteristics are shown in Table 1. In 5% of STEMI patients no primary PCI was 
performed because the coronary occlusion had resolved spontaneously. Median myocardial 
ischemia time was 3.2 (2.5-4.3) hours for STEMI.
Differences in skin AF between groups 
Skin AF was measured at a median of 21.2 (12.3-28.2) hours after symptom onset (63% 
<24h; 27% 24h-48h; 11% >48h) and 16.6 (8.8-16.6) hours after PCI in STEMI patients. 
Figure 1 demonstrates that skin AF was signiﬁ cantly higher in STEMI compared with sCAD 
and controls. Also in sCAD, skin AF was signiﬁ cantly greater than in controls. These between-
group differences in skin AF remained signiﬁ cant after correction for diabetes, smoking, 
cholesterol, and serum creatinine (F=5.2, η2=0.035, P=0.024 for STEMI compared with 
sCAD and F=8.9, η2=0.079, P=0.004 for STEMI compared with controls). 
Skin AF and markers for glycemic and inﬂ ammatory stress within STEMI group
Skin AF correlated positively with age (r=0.44; P<0.001), HbA1c (r=0.43; P<0.001), and 
glucose (r=0.24; P=0.027), negatively with systolic blood pressure (r=-0.23; P=0.034), 
and was higher in subjects with CRP >4 mg/l (P=0.007) or with previous CVD (P<0.001). 
Skin AF was not signiﬁ cantly associated with lipid parameters, peak cardiac enzymes, or 









cardiac enzymes, and gender, age (β, 0.24; 95% CI, 0.02-0.46; P=0.033), CRP (β, 0.26; 
95% CI, 0.05-0.48; P=0.018), HbA1c (β, 0.36; 95% CI, 0.14-0.58; P=0.002), and previous 
CVD (β, 0.24; 95% CI, 0.01-0.44; P=0.042) were independently associated with skin AF 
(r2=0.45; P<0.001). 
Follow-up measurement and one year incidence of composite endpoint in STEMI
Patients measured within 200 days following STEMI (N=15) did not show a signiﬁ cantly 
decrease in skin AF, however in patients measured >200 days after STEMI (N=14) skin AF 
did decrease signiﬁ cantly (P=0.018). Figure 2 demonstrates that during one year follow-
up, the composite endpoint occurred in 11 patients; 4 patients died, 4 were hospitalized 
for a new myocardial infarction and 3 for heart failure and that patients with skin AF values 
above the median (2.5 *10-2 AU) had a hazard ratio of 11.6 (95% CI, 1.5-90.8; P=0.019) 
for developing MACE. Partial corrections for potential confounders revealed that skin AF 
predicted MACE independent of age (hazard ratio 8.7, 95% CI 1.0-74.4; P=0.048), sex 
(10.3, 1.3-83.7; 0.030), current smoking (10.5, 1.3-84.1; 0.027), peak troponin levels 
Table 1. Clinical characteristics of study groups
 
 STEMI (n = 88) sCAD (n = 81) Controls (n = 32)
Age (yrs) 64 ± 13 64 ± 10 63 ± 11
Men 67 (76%) 60 (74%) 23 (72%)
Current smokers 36 (44%)*†  15 (20%)‡ 0 (0%)
Diabetes mellitus 25 (28%)*† 12 (15%)‡ 0 (0%)
         known 11 (13%)† 12 (15%)‡ 0 (0%)
         new onset 14 (16%)*† 0 (0%) 0 (0%)
CrCl (ml/min./1.73 m2) 80 ± 28 74 ± 25 81 ± 21
Glucose (mg/dL) 130 (111 - 160)*† 92 (83 - 106)‡ 86 (83 - 95)
Cholesterol (mg/dL) 215 ± 39* 183 ± 39‡ 222 ± 31
BMI (kg/m2) 27 ± 3 27 ± 4 25 ± 3
Vascular history      
         previous ACS 6 (7%)* 27 (34%) 0 (0%)
         previous PTCA 3 (3%)* 35 (44%)‡ 0 (0%)
         previous CABG 2 (2%)* 19 (24%)‡ 0 (0%)
         previous stroke 3 (3%) 4 (5%) 0 (0%)
         previous PAD 4 (5%) 10 (13%) 0 (0%)
Statin use 11 (13%)* 67 (85%)‡ 1 (3%)
Antihypertensive agent use      
         β-blocking agents  20 (23%)*† 63 (80%) 0 (0%)
         diuretics 8 (9%) 9 (11%) 1 (3%)
         ACE-inhibitors 7 (8%)* 28 (35%)‡ 2 (6%)
         ARBs  5 (6%) 10 (13%) 0 (0%)
         Calcium antagonists 5 (6%)* 38 (48%)‡ 0 (0%)
Aspirin use  7 (8%)* 62 (78%)‡ 0 (0%)
Data are mean ± SD, medium (quartiles), or number of subjects (%). Between group differences were 
tested with student’s t-test, or Fisher’s exact test when appropriate. * indicates P<0.05 for STEMI vs. 
sCAD; †, STEMI vs. controls; ‡, sCAD vs. controls. Medication use indicates situation before admission. 
STEMI = ST-elevation myocardial infarction; sCAD = stable coronary artery disease; CrCl = estimated 
Creatinine Clearance; BMI = body mass index; ACS = acute coronary syndrome; PTCA = percutaneus 
transluminal coronary angioplasty; CABG=coronary artery bypass graft; PAD = peripheral artery di-










































(12.3, 1.6-97.3; 0.017), anterior infarct location (11.1, 1.4-87.7; 0.022), previous 
myocardial infarction (12.4, 1.6-97.8; 0.017), admission systolic (11.7, 1.5-92.0; 0.019) or 
diastolic (11.5, 1.5-90.5; 0.020) blood pressure, glucose (10.3, 1.3-82.7; 0.028), or serum 
creatinine (11.2, 1.4-88.0; 0.022).
Discussion
In this study we demonstrate that skin AF is elevated in acute ST-elevation myocardial 
infarction compared with stable coronary artery disease and healthy controls. Even after 
multivariable adjustment for known confounders, skin AF remained signiﬁ cantly higher in 
Figure 1. Bar charts represent mean skin autoﬂ uorescen-
ce (AF) + standard error in healthy age and sex matched 
controls (HC) and patients with stable coronary artery di-
sease (sCAD) and <72 hours following ST-elevation myo-
cardial infarction (STEMI).  Comparisons between groups 
were corrected for multiple comparisons. Two last bars 
represent follow-up measurements of STEMI patients, 
<200 days (N=15) and >200 days (d) (N=14) after di-
scharge. AU indicates arbitrary units.
Figure 2.  Kaplan-Meier estimates of survival during one year follow-up with regard to the composite 
endpoint of all cause mortality and hospitalization for myocardial infarction or heart failure in patients 
with ST-elevation myocardial infarction in relation to skin autoﬂ uorescence (AF) below and above the 
median. Skin AF was <2.5 *10-2 AU in 46 and ≥2.5 AU *10-2 in 42 patients. CI indicates conﬁ dence 









STEMI, and was age independently related to CRP and HbA1c. The elevation of skin AF within 
72 hours following STEMI appeared to be partly of a transient nature, showing a tendency 
to decrease after 200 days. Furthermore, STEMI patients with an elevated skin AF were 
substantially more likely to die or to be hospitalized for a new myocardial infarction or heart 
failure in the following one year, which seemed to be independent of other risk factors such 
as age or infarction size. Our data suggest that skin AF may serve as a simple non-invasive 
measure of hyperglycaemia and inﬂ ammation derived oxidative stress involved in the 
development of ACS and may identify those patients with a potentially adverse outcome. 
Comparison with previous clinical studies using skin AF
In previous reports we have already demonstrated that skin AF is strongly related to skin 
accumulation of AGEs, as evidenced by a high correlation with speciﬁ c AGEs measured from skin 
biopsy homogenates12. Since these measured AGEs included both exclusively carbohydrate 
derived AGEs (pentosidine), but also mainly lipid derived AGEs (carboxymethyllysine and 
carboxyethyllysine), we concluded that skin AF may be a non-invasive marker for both 
glycation and oxidative stress15. This was also supported by the observation that skin AF 
was inversely related to plasma vitamin C levels, a strong antioxidant, in patients with 
renal failure16. Furthermore, subjects with diabetes, especially those with evidence of 
micro- or macrovascular disease, and subjects with renal failure had signiﬁ cantly higher 
levels of skin AF12;16;17 and skin AF was an independent predictor of CVD related mortality 
in these patients10;18. The data from the present study are in agreement with our previous 
observations, and suggest that skin AF may also be of potential use in euglycaemic patients 
without impaired kidney function.
Oxidative stress and AGEs in CVD
Data on the potential value of oxidative stress markers in endothelial dysfunction and 
clinically overt CAD is extensive1-6;19-22. Since most markers for oxidative stress require 
specialized laboratories, they are not readily available for clinical practice (23). AGEs are 
stable and non-invasively quantiﬁ able using skin AF and may, therefore, serve as a potential 
new marker in CVD. Data from other clinical studies support this hypothesis. Plasma AGEs 
have been shown to be associated with the number of stenotic coronary arteries in non-
diabetic subjects24, and to predict the long term incidence of cardiovascular mortality in 
non-diabetic women25. 
Basic research has shown that in atherosclerotic plaques AGEs interact with their receptor 
(RAGE), which results in increased production of inﬂ ammatory mediators and proteolytic 
enzymes, rendering plaques more vulnerable to rupture26. Recently, the key role of RAGE 
in the generation of oxidative stress and subsequent cellular damage was pointed out in an 
animal model of ischemia/reperfusion injury after myocardial infarction. It was demonstrated 
that lipoxidation derived AGEs are generated by ischemia/reperfusion and activate RAGE, 
thereby augmenting vascular and inﬂ ammatory cell activation. Animals lacking cellular 
expression of RAGE were less susceptible to ischemia/reperfusion damage27. This supports 
previous animal intervention studies showing that lowering AGE levels or antagonizing their 
receptors may attenuate the atherosclerotic process28-30. We recently reported that skin AF is 










































between inﬂ ammation and oxidative stress and skin AF by means of the AGE-RAGE axis26. In 
clinical studies it has been shown that lowering AGE in the circulation by dietary intake low in 
glycotoxins, results in marked decreases in serum levels of inﬂ ammatory mediators such as 
CRP and vascular adhesion molecule-131. Because in the present study skin AF was related 
to CRP, a marker of inﬂ ammation known to be strongly associated with CAD32, and predicted 
future events, our data are in agreement with the abovementioned reports. 
Study limitations
Due to the limited number of events in the one year follow-up period, it was impossible to 
differentiate between the individual contributions of all cause mortality, myocardial infarction, 
and heart failure. CRP was measured with a normal sensitivity kit with a detection limit of 
4 mg/dl. Because a signiﬁ cant number of patients had CRP levels <4 mg/dl it could only be 
analysed as a dichotomous variable. CRP and HbA1c could also not be included in the Cox 
regression analysis, because these were only measured in a subset of STEMI patients. More 
importantly, the small sample size did not allow for multivariable correction for more than one 
potentially confounding covariate in the Cox regression analysis. Additionally, because we 
measured skin AF after PCI, whether the elevation in skin AF was related to atherosclerotic 
plaque formation, ischaemia, or reperfusion, or a combination of those, cannot be determined 
from these data. Also, the observation that skin AF decreased after 200 days was based on a 
small number of patients, and should be considered as preliminary. The objection that skin AF 
was performed within a wide time range (i.e. some >72 hours after symptom onset) is valid, 
however we have seen that skin AF does not actually change in the ﬁ rst few days following 
STEMI (data not shown). In the current study, we did not measure circulating AGEs or other 
markers for oxidative stress. In order to determine the independent prognostic value of skin 
AF over these markers, a larger study in STEMI patients is warranted.  This would also make 
multivariable correction possible in the Cox proportional hazard model. For it to be of clinical 
use in STEMI patients, it should add incremental information to currently available risk 
scores such as the Thrombolysis In Myocardial Infarction (TIMI), Platelet glycoprotein IIb/
IIIa in unstable Agina: Receptor Suppression Using Integrilin (PURSUIT), and Global Registry 
of Acute Coronary Events (GRACE) risk score. Finally, we are currently studying its value 
in patients with unstable angina or non ST-elevation myocardial infarction. These patients 
are more of a challenge, since it is currently very difﬁ cult to select those patients that are 
at the highest risk of an adverse outcome. From previous investigations we have learned 
that skin AF cannot be reliably measured in subjects with skin photo type V-VI33. Therefore, 
for this study we excluded these skin types and further development for improving the 
measurement in dark skin types is ongoing and a newer version of the instrument is capable 
of reliably measuring skin AF in darker skin types. Since not all AGEs encompass ﬂ uorescent 
properties, skin AF is only representative of part of the total AGE burden. However, in our 
validation study we found that skin AF also correlated strongly with non-ﬂ uorescent AGEs12. 
Additionally, two major lipid peroxidation products, 4-hydroxynonenal and malondialdhyde 
— after binding to free aminogroups of protein — also encompass characteristic ﬂ uorescent 
properties34. Since the AGE-Reader covers a wide excitation/emission spectrum, skin AF 










To the best of our knowledge, this is the ﬁ rst study to demonstrate an association of a non-
invasive marker for cumulative hyperglycaemia and inﬂ ammation related oxidative stress 
with acute myocardial infarction. Despite the small sample size of this study, our prospective 
data do indicate that skin AF may provide an easily applicable tool to identify those patients 
at risk of developing major adverse cardiac events after myocardial infarction. However, 
since this was a relatively small study, these observations should be conﬁ rmed in a larger 
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